Human and Animal Dermal S9 Fractions now available as standard products

Subcellular fractions are widely used in drug discovery and preclinical drug development to evaluate the in vitro metabolism of new therapeutics. Skin fractions are already available from tebu-bio as catalogue items for CD1 Mouse and IGS Sprague Dawley Rat.

In collaboration with Sekisui XenoTech, tebu-bio is now adding human and minipig dermal subcellular fractions to the list of species available as standard test systems.

Protein biochemistry brings together a vast and varied world of methods of protein production, purification and characterization. Once you have successfully achieved the production of your protein in a selected system, you need to think about the following steps. Indeed, the quest does not stop there! The next step is purification, during which you will try to isolate your protein of interest from the surrounding contaminants while keeping it soluble and active. Your ultimate aim is to keep your protein “happy” by choosing the perfect buffer. You will be faced with a bewildering array of choices leading you to ask yourself “where do I start…?”.

Keep calm – it’s easy…

Reactive oxygen species (ROS) play key roles in various intracellular processes and have been shown to be involved in many diseases (eg. carcinogenesis, inflammation…). Each of the ROS species is likely to have a specific role in living cells. Therefore, there is an emerging need for selectively detecting each species of ROS through conventional biochemical assays, but also in live cell imaging (see a previous post “Reactive Oxygen Species (ROS) and related assay kits“).

Neutralizing MAb Anti-Human Interferon Lambda Receptor 1, Clone MMHLR-1 – PBL Assay Sciences at tebu-bio

PBL Assay Sciences offer a new monoclonal antibody to neutralize Human Interferon (IFN) activity, the Anti-Human Interferon Lambda Receptor 1, Clone MMHLR-1 (MAb).

This antibody is suitable for use in Type III IFN neutralization, flow cytometry, immunohistochemistry and immunoprecipitation. It neutralizes biological activity of human Type III IFNs (IFN lambda 1, 2 & 3, i.e. IL-29, IL-28A & IL-28B, respectively) at the Lambda Receptor 1 (i.e. IL-28 Receptor 1), and blocks Type I interferon receptor complex.

This complements the existing offer of antibodies and proteins to neutralize human and mouse IFN activities, available across Europe through tebu-bio’s network of local offices.